Cephalexin Dosing for Pediatric Skin Infections
For children with skin infections, cephalexin should be dosed at 25-50 mg/kg/day divided into 3-4 doses per day (typically 25 mg/kg/day in 4 divided doses). 1
Recommended Dosing Regimen
Based on the most recent guidelines from the Infectious Diseases Society of America:
- Standard dosing: 25 mg/kg/day divided into 4 doses 1
- Dose range: 25-50 mg/kg/day 1
- Duration: 7-10 days, depending on clinical response 1
For skin infections specifically caused by Staphylococcus aureus (MSSA):
Alternative Dosing Options
Recent research suggests that less frequent dosing may be effective while improving adherence:
- Three times daily option: 45 mg/kg/dose (maximum 1.5 g) three times daily 2
- Twice daily option: 22-45 mg/kg twice daily for MSSA with lower MICs (1-2 mg/L) 3
Dosing Considerations
Age-specific considerations:
- Children over 1 year: Follow the standard weight-based dosing above
- Adolescents ≥15 years: May use adult dosing of 250-500 mg every 6 hours 4
Severity considerations:
- Mild infections: Lower end of dosing range (25 mg/kg/day)
- Moderate to severe infections: Higher end of dosing range (50 mg/kg/day) 1
- Severe infections: May require up to 100 mg/kg/day in divided doses 4
Common Pitfalls and Caveats
Underdosing: Inadequate dosing may lead to treatment failure and potential development of resistance.
Adherence challenges: The standard four-times-daily dosing can be difficult for families to maintain. Consider the three-times-daily regimen (45 mg/kg/dose) if adherence is a concern 2.
Penicillin allergy: Cephalexin is a first-generation cephalosporin and should be used with caution in patients with immediate hypersensitivity reactions to penicillin due to potential cross-reactivity 1.
Duration of therapy: For streptococcal skin infections, ensure a full 7-10 day course is completed to prevent complications 1.
Monitoring: Watch for common side effects including diarrhea, nausea, or rash. Rarely, neutropenia may occur with higher doses 2.
Cephalexin remains a first-line agent for skin infections in children due to its excellent coverage of the most common causative pathogens (Staphylococcus aureus and Streptococcus pyogenes), favorable safety profile, and established efficacy.